Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sharmila Lilland

Nurse Practitioner, Gerontology Venice, FL Nurse Practitioner

NPI 1114571098 CMS profile 10624531

901 Tamiami Trl S, Ste A2, Venice, FL 34285

Open in the dashboard

General payments

$5,772

192 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sharmila Lilland of Venice, FL is reported in the CMS Open Payments database as having received $5,772 across 192 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,831 21
2024 General $1,979 72
2023 General $876 40
2022 General $810 44
2021 General $276 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sharmila Lilland
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Sharmila Lilland were reported at $1,831. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Sharmila Lilland Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $276 $133 $44–$396 $132
2022 $810 $142 $48–$452 $149
2023 $876 $158 $53–$482 $160
2024 $1,979 $171 $55–$533 $164
2025 $1,831 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $1,686 31 payments
  2. Daiichi Sankyo Inc. $634 15 payments
  3. E.R. Squibb & Sons, L.L.C. $374 22 payments
  4. Amgen Inc. $331 7 payments
  5. Eisai Inc. $223 10 payments
  6. Lilly USA, LLC $217 6 payments
  7. AstraZeneca Pharmaceuticals LP $173 8 payments
  8. Celgene Corporation $165 9 payments
  9. Syndax Pharmaceuticals, Inc. $149 1 payment
  10. Genzyme Corporation $149 7 payments
  11. Other $1,671 76 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,309 177 payments
  2. Long term medical supply or device loan $1,463 15 payments
Products named General payments · program years 2021–2025
  1. KISQALI $1,583 25 payments
  2. ENHERTU Oncology $634 15 payments
  3. OPDIVO $289 18 payments
  4. Blincyto $261 3 payments
  5. Lenvima $223 10 payments
  6. BRUKINSA $121 5 payments
  7. VERZENIO $113 5 payments
  8. LIBTAYO $112 6 payments
  9. KEYTRUDA $106 4 payments
  10. ENHERTU Oncology $90 4 payments
  11. Other $2,601 134 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 2 billing codes

Paid by Medicare

$1,087

Medicare's payments for the services billed

Medicare patients

14

Average age 72

Services billed

26

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KISQALI
  • Novartis Pharmaceuticals Corporation $472
$472 — —
ENHERTU
  • Daiichi Sankyo Inc. $376
  • AstraZeneca Pharmaceuticals LP $27
$403 — —
Lenvima
  • Eisai Inc. $127
$127 — —
OPDIVO
  • E.R. Squibb & Sons, L.L.C. $94
$94 — —
BRUKINSA
  • BeiGene USA, Inc. $74
$74 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

192 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record